Skip to content
Alefacept
Amevive (alefacept) is a protein pharmaceutical. Alefacept was first approved as Amevive on 2003-01-30. It is used to treat psoriasis in the USA. The pharmaceutical is active against T-cell surface antigen CD2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Alefacept
Tradename
Proper name
Company
Number
Date
Products
AmevivealefaceptAstellas Pharma US, Inc.N-125036 DISCN2003-01-30
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
psoriasisEFO_0000676D011565L40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA15: Alefacept
HCPCS
Code
Description
J0215
Injection, alefacept, 0.5 mg
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40—446519
Atopic dermatitisD003876EFO_0000274L20—1—1—2
Pityriasis rubra pilarisD010916L44.0———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft vs host diseaseD006086D89.81—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney transplantationD01603011——13
Psoriatic arthritisD015535EFO_0003778L40.5—1———1
Lichen planusD008010L43—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Aplastic anemiaD000741HP_0001915D61.91———12
LymphomaD008223C85.91————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alopecia areataD000506EFO_0004192L63————11
Sickle cell anemiaD000755EFO_0000697D57————11
ThalassemiaD013789EFO_1001996D56————11
Wiskott-aldrich syndromeD014923D82.0————11
Diamond-blackfan anemiaD029503D61.01————11
Shwachman-diamond syndromeD000081003————11
Fanconi anemiaD005199Orphanet_84D61.09————11
Chronic granulomatous diseaseD006105EFO_0000338D71————11
Dyskeratosis congenitaD019871————11
Chediak-higashi syndromeD002609Orphanet_167D72.0————11
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameALEFACEPT
INNalefacept
Description
Lymphocyte function-associated antigen 3 precursor (Ag3) (Antigen CD58)
Classification
Protein
Drug classreceptor molecules or membrane ligands, natural, modified or modified: lymphocyte function-associated antigen 3 (LFA) receptors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID222535-22-0
RxCUI299635
ChEMBL IDCHEMBL1201571
ChEBI ID—
PubChem CID—
DrugBankDB00092
UNII IDELK3V90G6C (ChemIDplus, GSRS)
Target
Agency Approved
CD2
CD2
Organism
Homo sapiens
Gene name
CD2
Gene synonyms
SRBC
NCBI Gene ID
914
Protein name
T-cell surface antigen CD2
Protein synonyms
CD2, CD2 antigen (p50), sheep red blood cell receptor, Erythrocyte receptor, LFA-2, LFA-3 receptor, lymphocyte-function antigen-2, Rosette receptor, T-cell surface antigen T11/Leu-5
Uniprot ID
P06729
Mouse ortholog
Cd2 (12481)
T-cell surface antigen CD2 (Q61394)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,102 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,367 adverse events reported
View more details